semaglutide for liver disease Receives FDA Approval Treatment of MASH Liver disease: Diabetes and weight

Semaglutide may do more than curb cravingsit can alter the sensory enjoyment of food

SURMOUNT-1 demonstrated average weight loss of approximately 21% at the highest dose

Although the oral medications are easier to take, they have less bioavailability compared to injectable medications and may be less effective for weight loss and blood sugar control

Conversely, patients who are already close to their glycaemic target may see only modest numerical improvements

Avoid lying down immediately after eating, as delayed gastric emptying can worsen reflux symptoms

While you cannot obtain GLP-1 directly from food, your dietary choices profoundly influence how much GLP-1 your own intestinal cells produce and release